recombinant human il 27  (R&D Systems)

Journal: eBioMedicine

Article Title: Interleukin-27 remodels the bone marrow niche to suppress B-cell development and leukaemia progression in mouse models

doi: 10.1016/j.ebiom.2026.106239

Figure Lengend Snippet: IL-27 impairs early B-cell development in the bone marrow. (A) Experimental scheme for AAV-mediated IL-27 delivery and analysis of splenic and BM B-cell compartments. (B–D) Splenic B-cell analysis 10 weeks after AAV-Ctrl or AAV-IL-27 treatment (n = 2 per group). (B) Frequency of total splenic B cells. (C) CIBERSORTx-based deconvolution of splenic B-cell subsets, including clustering and pseudotime analysis (left) and relative subset distribution (right). (D) Cd93 expression (TPM) in splenic B cells. (E–G) Analysis of splenic and BM B-cell compartments 3 weeks after treatment (n = 4 per group). (E) Representative flow cytometry plots. (F) Frequencies of B220 + CD19 − and B220 − CD19 + populations in the BM and spleen. (G) Relative distribution of B-cell developmental subsets in the BM. (H–I) Kinetics of B-cell populations following IL-27 treatment (n = 2 per group at each time point). (H) Frequency and absolute number of BM B220 + B cells. (I) Proportions of B-cell subsets within the B220 + compartment at the indicated time points. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001; ns, not significant; unpaired Student's t-test.

Article Snippet: Cells were treated with recombinant murine IL-27 (51107-M08H, Sino Biological) or human IL-27 (50 ng/mL) for 24 h prior to RNA extraction.

Techniques: Cell Analysis, Expressing, Flow Cytometry

Journal: eBioMedicine

Article Title: Interleukin-27 remodels the bone marrow niche to suppress B-cell development and leukaemia progression in mouse models

doi: 10.1016/j.ebiom.2026.106239

Figure Lengend Snippet: Exogenous IL-27 inhibits CLP formation in the bone marrow. (A) qPCR analysis of B-lineage- and myeloid-associated transcription factors in BM cells 5 days after AAV-Ctrl or AAV-IL-27 administration (n = 3 per group). (B) qPCR analysis of CEBPA expression in Reh cells treated with hIL-27 and DAC for 3 days (n = 3 per group). (C–D) Frequencies and absolute numbers of CLPs in WT and CD19 Cre ;IL-27R fl/fl mice (n = 3 per group). (E–F) BM B-cell frequency (E) and proportion of B220 + CD43 hi IgM − B cells (F) in WT and CD19 Cre ;IL-27R fl/fl mice 2 weeks after AAV treatment (n = 3 for WT Ctrl group; n = 3 for WT IL-27 group; n = 3 for CD19 Cre Ctrl group; n = 4 for CD19 Cre IL-27 group). (G–H) BM B-cell frequency (G) and proportion of B220 + CD43 hi IgM − B cells (H) in CD4 Cre ;IL-27R fl/fl and Lyz2 Cre ;IL-27R fl/fl mice 2 weeks after AAV treatment (n = 3 for CD4 Cre Ctrl group; n = 3 for CD4 Cre IL-27 group; n = 5 for Lyz2 Cre Ctrl group; n = 6 for Lyz2 Cre IL-27 group). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001; ns, not significant; unpaired Student's t-test.

Article Snippet: Cells were treated with recombinant murine IL-27 (51107-M08H, Sino Biological) or human IL-27 (50 ng/mL) for 24 h prior to RNA extraction.

Techniques: Expressing

Journal: eBioMedicine

Article Title: Interleukin-27 remodels the bone marrow niche to suppress B-cell development and leukaemia progression in mouse models

doi: 10.1016/j.ebiom.2026.106239

Figure Lengend Snippet: Exogenous IL-27 reshapes immune reconstitution after bone marrow transplantation. (A) Experimental scheme. WT mice underwent BM transplantation followed by AAV-Ctrl or AAV-IL-27 treatment. Splenic and BM immune reconstitution was analysed at 10 weeks after treatment (n = 4 mice for the Ctrl group; n = 5 mice for the IL-27 group). (B) Percentages and absolute numbers of CD45 + splenocytes. (C–F) Frequencies of major immune cell populations within CD45 + splenocytes: myeloid cells (C), macrophages (D), T and B cells (E), and NK cells (F). (G) Frequency of CD4 + T cells among splenic T cells. (H) Proportion of Tregs among CD4 + T cells. (I–J) BM B-cell reconstitution. Frequency of BM B220 + B cells (I) and distribution of B220 + B-cell subsets (J). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001; ns, not significant; unpaired Student's t-test.

Article Snippet: Cells were treated with recombinant murine IL-27 (51107-M08H, Sino Biological) or human IL-27 (50 ng/mL) for 24 h prior to RNA extraction.

Techniques: Transplantation Assay

Journal: eBioMedicine

Article Title: Interleukin-27 remodels the bone marrow niche to suppress B-cell development and leukaemia progression in mouse models

doi: 10.1016/j.ebiom.2026.106239

Figure Lengend Snippet: IL-27 inhibits B-cell development through both direct and indirect mechanisms. (A) Schematic of the BM chimera model. WT (WTR) or IL-27R −/− (KOR) recipients were treated with AAV-Ctrl or AAV-IL-27. Donor BM cells were a 1:1 mix of WT (CD45.1 + ) and IL-27R −/− (CD45.1 − ) cells. Analyses were performed at 5 weeks (B–E; n = 3 per group) or 10 weeks (F–I; n = 5 per group) post-transplantation. (B) Percentage of CD19 + B cells from CD45.1 + or CD45.1 − (IL-27R −/− ) donors in spleen and BM of WTR and KOR mice. (C) Absolute numbers of total CD19 + B cells in spleen and BM of WTR and KOR mice. (D) Absolute numbers of CD19 + B cells from CD45.1 + or CD45.1 − (IL-27R −/− ) donors in spleen and BM of WTR and KOR mice. (E) Percentage of B220 + CD19 − B cells from CD45.1 + or CD45.1 − (IL-27R −/− ) donors in BM of WTR and KOR mice. (F) Absolute numbers of B220 + CD19 - B cells from CD45.1 + or CD45.1 - (IL-27R −/− ) donors in BM of WTR and KOR mice. (G) Frequencies and absolute numbers of BM B220 + B cells derived from CD45.1 + or IL-27R −/− donors in WTR mice. (H) Proportion of CD43 hi IgM − subsets from CD45.1 + or IL-27R −/− donors in BM B220 + B cells in WTR mice. (I–J) Frequencies of CLPs (I) and their donor-specific contributions (J) in BM chimeras. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001; ns, not significant; unpaired Student's t-test.

Article Snippet: Cells were treated with recombinant murine IL-27 (51107-M08H, Sino Biological) or human IL-27 (50 ng/mL) for 24 h prior to RNA extraction.

Techniques: Transplantation Assay, Derivative Assay

Journal: eBioMedicine

Article Title: Interleukin-27 remodels the bone marrow niche to suppress B-cell development and leukaemia progression in mouse models

doi: 10.1016/j.ebiom.2026.106239

Figure Lengend Snippet: Exogenous IL-27 indirectly inhibits BM B-ALL cells. (A) Experimental design. GFP + B-ALL cells were transferred into WT mice, followed by AAV-Ctrl or AAV-IL-27 administration. BM and splenic B-ALL cells were analysed 9–10 days later (n = 3 per group). (B–C) Representative flow cytometry plots and quantification of GFP + B-ALL and GFP − B cells. (D) GSVA analysis of transcriptional changes in BM B-ALL cells isolated from mice in (A). (E) Gene Ontology (GO) enrichment analysis of DEGs between Ctrl and IL-27 groups in (A) (adjusted P < 0.05, |log 2 fold change| > 1). The outer ring indicates enriched GO terms, the middle ring represents relative gene expression changes in the IL-27 group, and the inner ring shows background gene counts, with colour intensity reflecting enrichment significance. Enriched pathways include interferon-γ-mediated signalling, interferon-β responses, adhesion-related processes, protozoan defence responses, calmodulin-dependent kinase signalling, and negative regulation of STAT tyrosine phosphorylation. (F–G) Expression of apoptosis- and cell cycle-related genes in BM B-ALL cells from (A). (H) Experimental design. WT and IL-27R −/− mice transplanted with GFP + B-ALL cells were treated with AAV-Ctrl or AAV-IL-27 (n = 4 for WT Ctrl group; n = 4 for WT IL-27 group; n = 5 for IL-27R −/− Ctrl group; n = 5 for IL-27R −/− IL-27 group). (I–J) Representative flow plots and quantification of BM B-ALL cells. (K–L) Flow cytometry plots and quantification of BM B-ALL cells in CD4 Cre ;IL-27R fl/fl , CD19 Cre ;IL-27R fl/fl , and Lyz2 Cre ;IL-27R fl/fl mice (n = 2 for CD4 Cre Ctrl group; n = 2 for CD4 Cre IL-27 group; n = 3 for CD19 Cre Ctrl group; n = 3 for CD19 Cre IL-27 group; n = 3 for Lyz2 Cre Ctrl group; n = 3 for Lyz2 Cre IL-27 group). (M) Flow cytometry plots and quantification of BM B-ALL cells in Rag1 −/− mice (n = 3 per group). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001; ns, not significant; unpaired Student's t-test.

Article Snippet: Cells were treated with recombinant murine IL-27 (51107-M08H, Sino Biological) or human IL-27 (50 ng/mL) for 24 h prior to RNA extraction.

Techniques: Flow Cytometry, Isolation, Gene Expression, Phospho-proteomics, Expressing

Journal: eBioMedicine

Article Title: Interleukin-27 remodels the bone marrow niche to suppress B-cell development and leukaemia progression in mouse models

doi: 10.1016/j.ebiom.2026.106239

Figure Lengend Snippet: IL-27 reshapes the BM niche, reducing B-cell support and leukaemogenesis. (A) Pseudotime analysis of BM B-cell subsets (C0–C10). (B) Expression of representative marker genes across B-cell clusters in (A). (C–G) BM cells were harvested 8 days after AAV-Ctrl or AAV-IL-27 administration for RNA-seq analysis (n = 3 per group). (C) CIBERSORTx analysis showing increased pre-pro-B and cycling pro-B subsets after IL-27 treatment. (D) KEGG pathway enrichment analysis highlighting alterations in adhesion-related pathways. (E–F) Heatmaps of transcription factors (E) and adhesion molecules (F). (G) RNA-seq analysis of genes shown in the figure in BM cells. (H) RNA-seq analysis of genes shown in the figure in human MSCs with or without hIL-27 treatment (n = 2 per group). (I) qPCR analysis of genes shown in the figure in murine MSCs with or without IL-27 (n = 3 per group). (J) RNA-seq analysis of genes shown in the figure in BM Gr-1 + cells 3 weeks after AAV-Ctrl or AAV-IL-27 administration (n = 2 per group). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001; ns, not significant; unpaired Student's t-test.

Article Snippet: Cells were treated with recombinant murine IL-27 (51107-M08H, Sino Biological) or human IL-27 (50 ng/mL) for 24 h prior to RNA extraction.

Techniques: Expressing, Marker, RNA Sequencing

Journal: eBioMedicine

Article Title: Interleukin-27 remodels the bone marrow niche to suppress B-cell development and leukaemia progression in mouse models

doi: 10.1016/j.ebiom.2026.106239

Figure Lengend Snippet: IL-27 exhibits therapeutic potential while modulating B-cell compartments. (A–B) Experimental design of combination therapy in WT (A) and Rag1 −/− (B) mice, with corresponding Kaplan–Meier survival analysis. (C–D) Experimental design of IL-27R −/− CAR-T cell therapy combined with AAV-Ctrl or AAV-IL-27 in B-ALL-bearing mice, with Kaplan–Meier survival curves. B-ALL cells were transplanted either prior to chemotherapy (C) or after chemotherapy (D). (E–F) NSG mice transplanted with human G-PBSCs were injected intramuscularly with AAV-Ctrl or hIL-27. 10 days later, frequencies and absolute numbers of B cells in the BM and spleen were analysed (n = 5 per group). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001; ns, not significant; log-rank test (A–D) and unpaired Student's t-test (E–F).

Article Snippet: Cells were treated with recombinant murine IL-27 (51107-M08H, Sino Biological) or human IL-27 (50 ng/mL) for 24 h prior to RNA extraction.

Techniques: Injection

Journal: Nature Communications

Article Title: Interleukin-27 is antiviral against Zika virus at the maternal-fetal interface

doi: 10.1038/s41467-025-67378-0

Figure Lengend Snippet: Representative brightfield images of single trophoblast organoid (TO) culture at 1-, 3-, and 6-days post-passage. 5X magnification, scale bar 1000 μm (top). Insets denote area captured at 10X magnification, scale bar 200μm (bottom). For all 4 biological TO donors, experiment was repeated independently >4 times with similar results. B Expression of IL-27 cytokine ( p28, EBI3 ) and receptor ( WSX1, gp130 ) subunit genes by decidual organoids (DOs) and TOs at day 6 post-passage as determined by quantitative RT-PCR, relative to housekeeping gene HPRT1 . Graphs represent 3 experimental replicates from 4 biological donors of TOs (circles, squares, triangles, and diamonds) and 3 biological donors of DOs (circles, squares, and triangles). Data presented as mean values ± SEM. C Conditioned media were collected from TO cultures from 3 biological donors at 1-, 24-, 48-, and 72-h post-passage and secreted IL-27 was measured via human IL-27 ELISA. Graph represents 5 experimental replicates per timepoint for donor 1 TOs (circles); Graph represents 3 experimental replicates per timepoint for donor 2 and 3 TOs (squares, triangles). Data presented as mean values ± SD. D Representative immunofluorescent images of TOs at day 6 post-passage. 10 μm TO cross-sections were stained for DAPI (blue), Ki67 for cytotrophoblasts (white), SDC1 for syncytiotrophoblasts (green), and IL27RA (magenta). White box indicates zoom inset and white dashed line demarcates regions of cytotrophoblasts (CTB) and syncytiotrophoblasts (STB). 20X magnification, Z-stack, merged. Scale bar, 100μm. Images representative experiments independently repeated in 4 biological TO donors with similar results. E. TOs from 2 biological donors (circles, diamonds) were pre-treated with neutralizing antibodies prior to infection with ZIKV-CAM, as described in Supplementary Fig. , . TO cultures were then collected at 1-, 24-, or 48-h post-infection (hpi) for RNA analysis. Graph displays ZIKV viral RNA expression in TOs as determined by quantitative RT-PCR relative to housekeeping gene HPRT1 , normalized to isotype control-treated organoids. Graph represents 4 independent infections preformed in first TO donor (circles) and 3 independent infections preformed in second TO donor (diamonds). Data presented as mean values ± SEM.

Article Snippet: IL-27 ELISA (R&D Systems, DY2526) was performed according to manufacturer’s protocol using CM from 3-5 replicate TO wells for 3 independent TO donors, and a 2-fold serial dilution standard curve of recombinant human IL-27 plated in technical duplicate.

Techniques: Expressing, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Staining, Infection, RNA Expression, Control

Journal: Nature Communications

Article Title: Interleukin-27 is antiviral against Zika virus at the maternal-fetal interface

doi: 10.1038/s41467-025-67378-0

Figure Lengend Snippet: A Table of experimental conditions for antiviral gene expression analyses in ( B , C ). B TO antiviral gene expression as determined by quantitative RT-PCR, relative to housekeeping gene HPRT1 . Graphs display 5 experimental replicates from 1 TO donor. Statistical analysis performed with multiple unpaired t-tests (two-sided Mann-Whitney), *p < 0.05 (adjusted p values = 0.023621). Data presented as mean values ± SEM. C TO antiviral gene expression as determined by quantitative RT-PCR, relative to Rux. Graphs display 5 experimental replicates from 1 TO donor. Statistical analysis performed with ordinary one-way Kruskal-Wallis ANOVA *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns=not significant ( MX1 from left, p = 0.0125, <0.0001, 0.0003, 0.2709; IFIT1 from left, p = 0.0031, <0.0001, 0.0001, 0.3945; OAS2 from left, p = 0.0141, <0.0001, 0.0012, 0.6252). Data presented as mean values ± SEM. D Left: Volcano plots depicting differentially expressed genes (DEGs) in IL-27-stimulated TOs and IFNλ-stimulated TOs. Statistical analysis performed via two-sided t-test with Benjamini-Hochberg False Discovery Rate correction. Vertical dashed lines: 0.5 log fold-change cutoffs; Horizontal dashed line: 0.05 adjusted p-value cutoff. Right: Venn diagram depicts total upregulated DEGs in IL-27- and IFNλ-stimulated conditions, with the 5 shared genes highlighted in red text on volcano plots. E Select upregulated pathways from gene set enrichment analysis (GSEA). Figure displays top 8 pathways by order of normalized enrichment score (NES). Numbers at end of bars indicate total number of genes associated with each term. Red asterisks indicate pathways that were enriched in both IL-27- and IFNλ-stimulated TOs. F ZIKV viral RNA expression in TOs at 24-h post-infection, as determined by quantitative RT-PCR relative to housekeeping gene HPRT1 , normalized to isotype control-treated organoids. Graph represents 6 independent infections in single TO donor. Statistical analysis performed with Kruskal-Wallis ANOVA, *p < 0.05, ***p < 0.001 (From left, p = 0.0383, 0.0480, 0.0003). Data presented as mean values ± SD. G Antiviral gene expression in ZIKV-infected TOs as determined by quantitative RT-PCR, relative to Isotype. Graphs display 5 experimental replicates from single TO donor. Statistical analysis performed with Kruskal-Wallis ANOVA *p < 0.05, **p < 0.01 ( IFIT1 from left, p = 0.0119, 0.0039; MX1 from left, p = 0.0484, 0.0019; PARP9 from left, p = 0.0033, 0.0163). Data presented as mean values ± SEM.

Article Snippet: IL-27 ELISA (R&D Systems, DY2526) was performed according to manufacturer’s protocol using CM from 3-5 replicate TO wells for 3 independent TO donors, and a 2-fold serial dilution standard curve of recombinant human IL-27 plated in technical duplicate.

Techniques: Gene Expression, Quantitative RT-PCR, MANN-WHITNEY, RNA Expression, Infection, Control

Journal: Nature Communications

Article Title: Interleukin-27 is antiviral against Zika virus at the maternal-fetal interface

doi: 10.1038/s41467-025-67378-0

Figure Lengend Snippet: A Whole placental lysates (placenta and decidua) were collected from uninfected C57BL/6 mice at E9.5, E13.5, and E17.5 of gestation, and IL-27 protein levels were measured via ELISA. Each data point represents IL-27 concentration of an individual placenta. For E9.5 and E13.5, graph represents placentas obtained from 2 independent litters; For E17.5, graph represents placentas obtained from one independent litter. Data presented as mean values ± SD. B Schematic represents breeding schemes used to delineate maternal and fetal p28 production in uninfected murine placentas and deciduas. Left: p28-GFP −/− dam x p28-GFP +/− sire crosses were used to generate placental tissues that lacked (I., p28-GFP Null ) or expressed fetal-derived p28-GFP (II., p28-GFP F ). Right: p28-GFP +/− dam x p28-GFP −/− sire crosses were used to generate placental tissues that retained maternal p28-GFP expression only (III., p28-GFP M ) or expressed both maternal- and fetal-derived p28-GFP (IV., p28-GFP FM ). Created in BioRender. Jurado, K. (2025) https://BioRender.com/lkflcs6 . C Representative immunofluorescent image of an uninfected p28-GFP F placenta at E13.5 of gestation. Yolk sac (Ys), labyrinth (Lb), junctional zone (Jz), and maternal decidua (Dc) regions were determined via immunofluorescence staining of endothelial cells (CD31; white) and nuclei (DAPI; blue). 20X magnification, stitched. Scale bar, 1000 μm. Image shown is representative of experiments repeated independently in >4 p28-GFP F placentas from separate litters. D Representative immunofluorescent images of p28-GFP within uninfected murine deciduas at E13.5. 10 μm placental cross-sections were obtained for all conditions in Fig. 3B and stained with anti-GFP (green) and DAPI (blue). Images representative of 4 placentas per condition. 20X magnification, zoomed. Scale bar 100 μm. E Quantification of total p28-GFP signal area (microns ) in decidua and labyrinth regions of uninfected placentas, as determined by ImageJ software. Graph represents measurements from 2-4 independent placentas per group, with 3-4 cross-sections obtained per placenta, and 4-8 images acquired per cross-section (Decidua: p28-GFP null n = 42, p28-GFP F n = 59, p28-GFP M n = 53, p28-GFP FM n = 69; Labyrinth: p28-GFP null n = 45, p28-GFP F n = 66, p28-GFP M n = 53, p28-GFP FM n = 68). Statistical analysis performed with Kruskal-Wallis ANOVA, *p < 0.05, **p < 0.001, ****p < 0.0001 (Decidua from left, p = <0.0001, <0.0001, <0.0001, 0.0136, >0.9999, <0.0001; Labyrinth from left, p = <0.0001, 0.0006, 0.0342, >0.9999, 0.3100, 0.8862). Data presented as mean values ± SD.

Article Snippet: IL-27 ELISA (R&D Systems, DY2526) was performed according to manufacturer’s protocol using CM from 3-5 replicate TO wells for 3 independent TO donors, and a 2-fold serial dilution standard curve of recombinant human IL-27 plated in technical duplicate.

Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay, Derivative Assay, Expressing, Immunofluorescence, Staining, Software

Journal: Nature Communications

Article Title: Interleukin-27 is antiviral against Zika virus at the maternal-fetal interface

doi: 10.1038/s41467-025-67378-0

Figure Lengend Snippet: A Timeline for mating and treatment of human STAT2 knock-in (hSTAT2 KI) mice with high molecular weight polyinosinic-polycytidylic acid (HMW poly(I:C)). Created in BioRender. Jurado, K. (2025) https://BioRender.com/eegilr9 . B Serum IL-6 levels in PBS- and HMW Poly(I:C)-treated dams at 6 h post-injection as determined via ELISA. n = 3 dams per group. Statistical analysis performed via ordinary two-way ANOVA, **p < 0.01, ns= not significant (From left, p = >0.9999, 0.0013, 0.0011, 0.9896). Data presented as mean values ± SD. C Proportion of fetuses exhibiting healthy, early resorption, or total resorption phenotypes at E13.5 in PBS- and HMW Poly(I:C)-treated dams. Graph displays total number of fetuses from 3-4 litters per condition. D Representative images depicting fetal outcomes at E13.5. Phenotypes were determined for each fetus based on gross morphology and tissue integrity, as described in methods. E Timeline for mating and infection of hSTAT2 KI mice, as described in methods. Created in BioRender. Jurado, K. (2025) https://BioRender.com/m1xcoc2 . F Proportion of fetuses exhibiting healthy, early resorption, or total resorption phenotypes at E13.5 in PBS- and ZIKV-infected dams. Fetal outcomes were evaluated in 3 independent litters for all conditions except ZIKV-infected IL27RA −/− dams, for which 4 independent litters were evaluated. Graph displays total number of fetuses per condition. G–I ZIKV burdens at E13.5 as determined via quantitative RT-PCR. G Combined ZIKV burden of one matching fetus and placenta, normalized to combined tissue weight. Shape of data point represents observed fetal phenotype. Total number of fetal/placental units per condition plotted (see 4 F ). Statistical analysis performed via Kruskal-Wallis ANOVA, ***p < 0.001, ns=not significant (From left, p = >0.9999, 0.0006). H Left: Fetal ZIKV burdens, normalized to fetus weights. Viral burdens for subset of fetuses exhibiting “healthy” phenotypes plotted (Isotype n = 24, α-IL-27 n = 16, IL27RA −/− n = 28). Right: Placental ZIKV burdens, normalized to placental weights. Viral burdens of placentas matched to fetuses with “healthy” phenotypes plotted (Isotype n = 24, α-IL-27 n = 16, IL27RA −/− n = 28). Statistical analysis performed via Kruskal-Wallis ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns=not significant (Fetal from left, p = >0.9999, 0.0374; Placental from left, p = 0.0378, <0.0001). I Maternal serum ZIKV burdens, normalized to serum weight. n = 3 dams for Isotype and α-IL-27-treated groups, n = 4 IL27RA −/− dams. Not significant via Kruskal-Wallis ANOVA.

Article Snippet: IL-27 ELISA (R&D Systems, DY2526) was performed according to manufacturer’s protocol using CM from 3-5 replicate TO wells for 3 independent TO donors, and a 2-fold serial dilution standard curve of recombinant human IL-27 plated in technical duplicate.

Techniques: Knock-In, High Molecular Weight, Injection, Enzyme-linked Immunosorbent Assay, Infection, Quantitative RT-PCR